Thrilled to share our recent paper published online today at Nature Cancer led by our talented postdoc Lo Chibaya and in collaboration with Lowe Lab and others at UMass Chan Medical School UMass Cancer Center Molecular, Cell and Cancer Biology and Memorial Sloan Kettering Cancer Center! rdcu.be/dbmYH nature.com/articles/s4301…

Very proud of Griffin Kane Griffin Kane and Meghan Brassil presenting their work at the 2023 Cancer Nanotechnology Gordon Research Conferences that focuses on tumor microenvironment immunomodulation! What an exciting meeting! UMass Biomedical Engineering UMass Cancer Center

Dr. Prabhani Atukorale (Prabhani Atukorale) is a recent recipient of the NIH R21 Trailblazer Award to develop nanotechnology-based vaccine “super adjuvants”. way to go, Dr. Atukorale!

Thanks to NIBIB Trailblazer support, we are growing our team UMass Biomedical Engineering UMass Cancer Center!! If you are interested in developing lipid-based nanoparticles as novel vaccine adjuvants for cancer, contact me! umass.edu/news/article/c…

If I could give aspiring scientists and trainees one piece of advice it would be this: Find a mentor who cares enough about you to do this 👇 #Mentorship #AcademicChatter #PhysicianScientist #CareerAdvice

Excited to share our latest preprint in collaboration with Prabhani Atukorale. Here we combined nanoparticles loaded with STING and TLR4 agonists with senescence-inducing therapies to activate Type I interferon signaling and T cell immunity in pancreatic cancer. biorxiv.org/content/10.110…

We are excited too! Here is our preprint in collaboration with Marcus Ruscetti Lab on the rational development of combination immunotherapies using nanoparticle platforms for aggressive cancers like PDAC

I hope that in the future, the unique lipid chemistry enabling mRNA vaccines will receive the highest recognition.

✨SPECIAL ISSUE: Immunoengineering for cancer✨ 🔖Latest REVIEW now in print from Prabhani Atukorale & colleagues UMass Biomedical Engineering: 'Engineering approaches for innate immune-mediated tumor microenvironment remodeling' Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

Our summer lab celebration has become a tradition with the Nandadasa lab TheNandadasaLab! Minus the badminton due to rain this year, but a proper party nonetheless to celebrate fellowships won, manuscripts accepted, exciting stories to come, and the true camaraderie of this group!

Delighted to share our opinion piece out today Trends in Immunology, led by Griffin Kane Griffin Kane and Meghan Brassil, with Miranda Diaz-Infante! Nanocarrier design takes center stage in pathogen-inspired technologies for cancer! UMass Biomedical Engineering UMass Cancer Center sciencedirect.com/science/articl…

Check out the latest opinion piece from our fabulous team! Here, we discuss the critical role of nanocarriers in the delivery of pathogen-inspired therapies. Thankful and proud to work with such talented colleagues who helped put this together. Hope you all enjoy!

Proud to share the results of several years of hard work from some incredibly talented teammates. A true collaborative effort combining our lipid nanoparticle technology with senescence inducing therapies. Always a pleasure working with the Ruscetti lab!

😎 Check out this recent Science Translational Medicine release, led by UMass Chan Medical School researchers Dr. Loretah Chibaya & Kelly DeMarco! Congratulations to the team! Prabhani Atukorale Marcus Ruscetti Lab 🎉 🔗 bit.ly/3T9BsWE

A multi-prong treatment combined with a clever delivery method has shown promise against one of the deadliest cancers. lifespan.io/news/combinati… by Arkadi Mazin #PancreaticCancer #senescence #SASP Marcus Ruscetti Lab Prabhani Atukorale PitarresiPhD Griffin Kane Jessica Peura

Innate immune activators packaged in lipid nanoparticles, and paired with two senescence-inducing chemotherapy agents, controlled tumor growth and extended survival in a mouse model of pancreatic ductal adenocarcinoma. Science Translational Medicine scim.ag/8eZ

Cancer vaccines and combination therapies, you say? Here's ⁦Griffin Kane⁩ and ⁦Miranda Diaz-Infante⁩ making the case for them ⁦AACR⁩ IO last week and representing the lab! ⁦UMass Biomedical Engineering⁩ ⁦UMass Cancer Center⁩ ⁦UMass Institute for Applied Life Sciences⁩

Thanks to ⁦UMass Institute for Applied Life Sciences⁩, here's one of our inaugural Translational Innovation Fellows ⁦Griffin Kane⁩ who presented today on his thesis work on new engineered cancer vaccines! Well done and kudos on flying the flag! ⁦UMass Biomedical Engineering⁩ ⁦UMass Cancer Center⁩

Honored to be featured by the Mass Founders Network! Huge thanks to Merrie Benjamin for the thoughtful write-up and to the entire WMHTC team for their incredible support. A big shoutout to my amazing advisor and co-founder, Dr. Prabhani Atukorale Check it out: massfoundersnetwork.org/journal/five-l…

Adjuvants can make or break it! Excited to share our paper Cell Reports Medicine, led by Griffin Kane, that makes the case for dual STING/TLR4 nanoparticles that "super adjuvant" cancer vaccines, protecting ~80% of mice across models. UMass Biomedical Engineering UMass Cancer Center cell.com/cell-reports-m…